AU768299B2 - Formulation for spray-drying large porous particles - Google Patents

Formulation for spray-drying large porous particles Download PDF

Info

Publication number
AU768299B2
AU768299B2 AU70666/00A AU7066600A AU768299B2 AU 768299 B2 AU768299 B2 AU 768299B2 AU 70666/00 A AU70666/00 A AU 70666/00A AU 7066600 A AU7066600 A AU 7066600A AU 768299 B2 AU768299 B2 AU 768299B2
Authority
AU
Australia
Prior art keywords
particles
salt
phospholipid
microns
multivalent salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU70666/00A
Other languages
English (en)
Other versions
AU7066600A (en
Inventor
Richard P. Batycky
Giovanni Caponetti
Michael M. Lipp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alkermes Inc
Original Assignee
Advanced Inhalation Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Inhalation Research Inc filed Critical Advanced Inhalation Research Inc
Publication of AU7066600A publication Critical patent/AU7066600A/en
Application granted granted Critical
Publication of AU768299B2 publication Critical patent/AU768299B2/en
Assigned to ALKERMES, INC. reassignment ALKERMES, INC. Alteration of Name(s) in Register under S187 Assignors: ADVANCED INHALATION RESEARCH, INC.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU70666/00A 1999-08-25 2000-08-23 Formulation for spray-drying large porous particles Ceased AU768299B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15066299P 1999-08-25 1999-08-25
US60/150662 1999-08-25
PCT/US2000/023118 WO2001013892A2 (en) 1999-08-25 2000-08-23 Large porous particles by spray-drying

Publications (2)

Publication Number Publication Date
AU7066600A AU7066600A (en) 2001-03-19
AU768299B2 true AU768299B2 (en) 2003-12-04

Family

ID=22535487

Family Applications (1)

Application Number Title Priority Date Filing Date
AU70666/00A Ceased AU768299B2 (en) 1999-08-25 2000-08-23 Formulation for spray-drying large porous particles

Country Status (7)

Country Link
EP (1) EP1210069B1 (enExample)
JP (1) JP2003507411A (enExample)
AT (1) ATE285755T1 (enExample)
AU (1) AU768299B2 (enExample)
CA (1) CA2383491A1 (enExample)
DE (1) DE60017152D1 (enExample)
WO (1) WO2001013892A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US7871598B1 (en) * 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
PT1280520E (pt) * 2000-05-10 2014-12-16 Novartis Ag Pós à base de fosfolípidos para administração de fármacos
US6848197B2 (en) * 2001-04-18 2005-02-01 Advanced Inhalation Research, Inc. Control of process humidity to produce large, porous particles
JP2004528339A (ja) * 2001-04-26 2004-09-16 ネクター セラピューティクス 気道に対して又は気道を介して高分子を送達するための新規方法及び組成物
GB0120123D0 (en) * 2001-08-17 2001-10-10 Upperton Ltd Preparation of microparticles
CA2465779A1 (en) * 2001-11-20 2003-05-30 Advanced Inhalation Research, Inc. Compositions for sustained action product delivery
ES2364636T3 (es) 2001-12-19 2011-09-08 Novartis Ag Administración pulmonar de aminoglucósidos.
AU2003287132B2 (en) * 2002-12-13 2009-03-12 Adagit Pharmaceutical porous particles
JP2012522009A (ja) * 2009-03-26 2012-09-20 パルマトリックス，インコーポレイテッド 肺炎および人工呼吸器関連気管気管支炎を治療および予防するための方法
RU2577698C2 (ru) 2009-03-26 2016-03-20 Пулмэтрикс, Инк. Сухие порошкообразные составы и способы лечения легочных заболеваний
CA2809666C (en) * 2010-08-30 2020-09-22 Michael M. Lipp Dry powder formulations and methods for treating pulmonary diseases
US20130164338A1 (en) 2010-08-30 2013-06-27 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
ES2710537T3 (es) * 2010-09-29 2019-04-25 Pulmatrix Operating Co Inc Polvos secos catiónicos
RU2640921C2 (ru) 2010-09-29 2018-01-12 Пулмэтрикс, Инк. Катионы одновалентных металлов сухих порошков для ингаляций
CA2865972C (en) 2012-02-29 2022-01-04 Pulmatrix, Inc. Inhalable dry powders
MX2015013845A (es) 2013-04-01 2016-05-09 Pulmatrix Inc Polvos secos de tiotropio.
AU2015213678C1 (en) 2014-02-10 2019-03-21 Respivant Sciences Gmbh Mast cell stabilizers treatment for systemic disorders
EP3104854B1 (en) 2014-02-10 2020-04-08 Respivant Sciences GmbH Mast cell stabilizers for lung disease treatment
CA2965759C (en) 2014-10-31 2023-12-12 Glaxosmithkline Intellectual Property Development Limited Powdered polypeptides with decreased disulfide impurities comprising divalent cationic materials
US10238625B2 (en) 2015-08-07 2019-03-26 Respivant Sciences Gmbh Methods for the treatment of mast cell related disorders with mast cell stabilizers
US10265296B2 (en) 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
CA3035528A1 (en) 2016-08-31 2018-03-08 Respivant Sciences Gmbh Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
AU2017339366A1 (en) 2016-10-07 2019-04-11 Respivant Sciences Gmbh Cromolyn compositions for treatment of pulmonary fibrosis
CA3133804A1 (en) * 2019-03-22 2020-10-01 Mannkind Corporation Inhalable dry powders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996032149A1 (en) * 1995-04-14 1996-10-17 Inhale Therapeutic Systems Pulmonary delivery of aerosolized medicaments
WO1997026863A1 (de) * 1996-01-24 1997-07-31 Byk Gulden Lomberg Chemische Fabrik Gmbh Verfahren zur herstellung von pulverförmigen lungensurfactant-zubereitungen
WO1998031346A1 (en) * 1997-01-16 1998-07-23 Massachusetts Institute Of Technology Preparation of particles for inhalation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5855913A (en) * 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996032149A1 (en) * 1995-04-14 1996-10-17 Inhale Therapeutic Systems Pulmonary delivery of aerosolized medicaments
WO1997026863A1 (de) * 1996-01-24 1997-07-31 Byk Gulden Lomberg Chemische Fabrik Gmbh Verfahren zur herstellung von pulverförmigen lungensurfactant-zubereitungen
WO1998031346A1 (en) * 1997-01-16 1998-07-23 Massachusetts Institute Of Technology Preparation of particles for inhalation

Also Published As

Publication number Publication date
EP1210069A2 (en) 2002-06-05
EP1210069B1 (en) 2004-12-29
DE60017152D1 (de) 2005-02-03
WO2001013892A3 (en) 2001-06-21
WO2001013892A2 (en) 2001-03-01
AU7066600A (en) 2001-03-19
JP2003507411A (ja) 2003-02-25
ATE285755T1 (de) 2005-01-15
CA2383491A1 (en) 2001-03-01

Similar Documents

Publication Publication Date Title
US7807200B2 (en) Formulations for spray-drying large porous particles
AU764738B2 (en) Use of simple amino acids to form porous particles
AU768299B2 (en) Formulation for spray-drying large porous particles
CA2341624C (en) Stable spray-dried protein formulations
US6956021B1 (en) Stable spray-dried protein formulations
US7252840B1 (en) Use of simple amino acids to form porous particles
US20040018243A1 (en) Modulation of release from dry powder formulations
EP1370246A2 (en) Modulation of release from dry powder formulations
AU2002242253A1 (en) Modulation of release from dry powder formulations
HK1101138A (en) Stable spray-dried protein formulations
EP1767195A2 (en) Stable spray-dried protein formulations

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)